DNAnexus and Discovery Life Sciences to Streamline Precision Health Data Analysis | Discovery Life Sciences Announces New CEO | Discovery Life Sciences Announces Major Strategic Expansions: New State-of-the-Art Facilities, Advanced Technologies, and Global Brand Enhancements | Discovery Life Sciences expands high-throughput proteomics services |

TruSight™ Oncology 500 (TSO500)

Streamlined Parallel Histopathology and NGS Workflows to Detect Clinically Relevant DNA and RNA Variants in Various Solid Tumor Indications

Discovery Genomics' TSO500 Solid Tumor NGS service provides high sensitivity detection of genomic variants across 523 DNA genes and 55 RNA fusion events in most major cancer indications and sample types, including microsatellite instability (MSI) and tumor mutational burden (TMB).

Applications

Our TSO500 NGS services provide pan-cancer genomic biomarker analysis of SNVs, InDels, CNVs, Fusions, TMB, and MSI to enable:

Discovery and verification of the presence of genomic biomarker targets and signatures in solid tumors
Retrospective identification of potential oncology clinical trial patient responders versus non-responders based on genomic profiles
RUO development and orthogonal validation of novel solid tumor diagnostic solutions
Combine the matching TSO500 Solid Tumor and TSO500 ctDNA applications to develop and validate non-invasive liquid biopsy assays from matched-patient Plasma and FFPE samples

Service Performance Data

Using commercially available reference standards in our optimized and automated nucleic acid extraction, library construction, and sequencing workflows, we demonstrate the accuracy, sensitivity, and reproducibility of our TSO500 ctDNA NGS service

ACCURACY:

>99%

LIMIT OF DETECTION:

> 2% Allele Fractions

Reproducability:

>97%

TSO500 Solid Tumor NGS Services Deliverables

TSO500HT v2.2 Output files

DNA Results

RNA Results

Combined DNA + RNA Results

QC and Metrics Files

Sample Input Requirements

FFPE extractions may be performed using Discovery Genomics' Dual DNA/RNA FFPE Extraction Method.
DNA Input: 80 - 120 ng, 500 ng max
RNA Input: 80 - 100 ng
RNA DV200 > 20%
DNA QC using Picogreen and RNA QC using Fragment Analyzer
DNA QC using Picogreen and RNA QC using Fragment Analyzer

TruSight™ Oncology 500 (TSO500)

Discovery Genomics' TSO500 Solid Tumor NGS service provides high sensitivity detection of genomic variants across 523 DNA genes and 55 RNA fusion events in most major cancer indications and sample types, including microsatellite instability (MSI) and tumor mutational burden (TMB).

Applications

Service Performance Data

ACCURACY:

>99%

LIMIT OF DETECTION:

> 2% Allele Fractions

Reproducability:

>97%

TSO500 Solid Tumor NGS Services Deliverables

Horizon FFPE gDNA Reference Control from Run 1

SeraCare NTRK Fusion Reference Control from Run 1

Colon Carcinoma Sample Report

TSO500HT v2.2 Output files

DNA Results

RNA Results

Combined DNA + RNA Results

QC and Metrics Files

Sample Input Requirements

Optimized Methods for Sequencing RNA from FFPE Samples

Related Products & Services

FFPE and Other Oncology Specimens

Optimized Dual DNA/RNA Extraction Services

Molecular Pathology Services

TSO500 Liquid Biopsy NGS Services

Other SequencingServices

Contact Us Today

May 2024

MARKETS WE SERVE

COMPANY

Markets We Serve

Resources

Popular Keywords

Categories,Pages

Quick Links

Technologies

Development and Clinical Trial Solutions

Tissues

Technologies

Development and ClinicalTrial Solutions

TSO500 Liquid Biopsy
NGS Services

Other Sequencing
Services

Development and Clinical
Trial Solutions

Development and Clinical
Trial Solutions